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A B S T R A C T
Recent clinical trials reported that increasing high-density lipoprotein-cholesterol (HDL-C) levels does not im-
prove cardiovascular outcomes. We hypothesize that HDL proteome dynamics determine HDL cardioprotective
functions. In this study, we characterized proteome profiles in HDL subclasses and established their functional
connection. Mouse plasma was fractionized by fast protein liquid chromatography, examined for protein, cho-
lesterial, phospholipid and trigliceride content. Small, medium and large (S/M/L)-HDL subclasseses were col-
lected for proteomic analysis by mass spectrometry. Fifty-one HDL proteins (39 in S-HDL, 27 in M-HDL and 29 in
L-HDL) were identified and grouped into 4 functional categories (lipid metabolism, immune response, coagu-
lation, and others). Eleven HDL common proteins were identified in all HDL subclasses. Sixteen, 3 and 7 proteins
were found only in S-HDL, M-HDL and L-HDL, respectively. We established HDL protein dynamic distribution in
S/M/L-HDL and developed a model of protein composition change during HDL maturation. We found that
cholesterol efflux and immune response are essential functions for all HDL particles, and amino acid metabolism
is a special function of S-HDL, whereas anti-coagulation is special for M-HDL. Pon1 is recruited into M/L-HDL to
provide its antioxidative function. ApoE is incorporated into L-HDL to optimize its cholesterial clearance
function. Next, we acquired HDL proteome data from Pubmed and identified 12 replicated proteins in human
and mouse HDL particle. Finally, we extracted 3 shared top moleccular pathways (LXR/RXR, FXR/RXR and
acute phase response) for all HDL particles and 5 top disease/bio-functions differentially related to S/M/L-HDL
subclasses, and presented one top net works for each HDL subclass. We conclude that beside their essencial
functions of cholesterol efflux and immune response, HDL aquired antioxidative and cholesterol clearance
functions by recruiting Pon1 and ApoE during HDL maturation.
1. Introduction
Epidemiologic studies have demonstrated that low high-density li-
poprotein-cholesterol (HDL-C) levels are a predictor of cardiovascular
disease (CVD) [1]. However, clinical trials reported that HDL-C eleva-
tion did not improve cardiovascular outcomes [2]. HDL is not only a
carrier of cholesterol for cellular cholesterol efflux and uptake but also a
complex of lipoproteins containing many proteins and other lipids that
influence HDL functions.
HDL is composed of a cholesterol core enriched with cholesterol
ester (CE) and triglyceride (TG), and surface lipid bilayer containing
free cholesterol (FC), phospholipid (PL) and proteins. Compared with
other lipoproteins, HDL is highly heterogeneous in size, charge and
composition, which are modified during HDL maturation from small to
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large HDL, This maturaturation process orchestrates reverse cholesterol
transport (RCT). HDL particles are usually divided into three subclasses
based on their size as small, medium and large (S, M, and L)-HDL. These
HDL subclass maybe different in their chemical and biological proper-
ties [3–5]. It was proposed that S-HDL primarily interacts with ABCA1
to mediate the efflux of cholesterol from peripheral cells, while L-HDL
interacts with SR-BI and ABCG1 to deliver cholesterol to the liver [6–9].
The understanding of HDL heterogeneity has greatly increased with
the progressive development of analytical technologies (Supplemental
Table 1). Difference in HDL density (1.063–1.210 g/mL) was first re-
cognized by gradient ultracentrifugation [10]. The first two HDL pro-
tein moieties, later known as ApoA1 and ApoA2, were identified in the
late 1960s using early electrophoresis methods [11]. Soon after, ApoE
was found in light/S-HDL, and ApoD was found in more dense/L-HDL
fractions [12,13]. Improvements in SDS-PAGE technology in the early
1980s revealed serum amyloid A (Saa) and ApoA4 in human HDL [14].
It was reported that 90% of plasma Pon1 is associated with ApoA1 and
present in HDL [15]. Approximately 200 distinct proteins were identi-
fied in HDL by different laboratories using mass spectrometry (MS)
technology [16–20], which permitted further exploration of HDL pro-
tein heterogeneity. Dr. Davidson reported 28 HDL proteins distributed
across five human HDL subpopulations (HDL2b, 2a, 3a, 3b and 3C),
identified by isopycnic density ultracentrifugation, and described cor-
relations among ApoL1, Pon1 and Pon3 functions to protect LDL oxi-
dation [21]. However, differential HDL proteomic analysis among HDL
subgroups has been limited, and systemic comparisons of HDL pro-
teomes across species have not been performed.
Unlike humans, detailed studies of the mouse lipoproteome are
scarce. Mice have significantly different lipid metabolism than humans.
For instance, they lack cholesteryl ester transfer protein (CETP), which
transfers CE from HDL to LDL and very-low-density lipoproteins (VLDL)
in humans. Thus, mice carry the majority of plasma cholesterol in HDL,
while humans carry much of it in LDL [22]. Therefore, mice have an
inherent advantage in resisting the development of atherosclerosis,
explaining the difficulty in establishing atherosclerotic mouse models
using genetic knockout methods. Although there are differences be-
tween the mouse and human lipoproteomes, mice share more simila-
rities with humans. Using gel filtration chromatography and MS ana-
lysis, Scott M. identified 113 lipid-associated proteins in mice and
compared the mouse lipoproteome and its size distribution to a pre-
vious human analysis. He demonstrated that protein diversity in the
LDL and HDL size ranges was similar in mice and humans, although
some distinct differences were noted. Furthermore, whether a given
protein was associated with L-versus S-HDL subclasses was also similar
between species [23]. A better understanding of the proteomic com-
position of mouse lipoproteins may offer additional explanations and
provide a stronger rationale for the use of mice to study human
atherosclerotic disease.
The purpose of this study used FPLC to identify differential HDL
proteomics in the S/M/L-HDL subclasses, try to make HDL subclasses
oversimplified and establish a subclasses proteomic feasible research
model, and also try to discover potential functional pathways of these
HDL subgroups, as determined by their protein heterogeneity.
2. Experimental procedures
2.1. Mouse model and plasma collection
ꟷ C57BL/6J male mice were used in this study. Animal studies were
approved by the Temple University Institutional Animal Care and Use
Committee (IACUC). Mice were fed a standard rodent chow (0% cho-
lesterol, 5.23% fat, 0.37% methionine, 2.39mg/g choline, 3.19mg/kg
folate, 54.6 μg/kg B12, 14.5 mg/kg B6, cat# 8640, Harlan Teklad,
Madison, WI) and fasted overnight. Blood sample was collected when
mice were at the age of 14–16 weeks by cardiac puncture and citrate
anticoagulation. Plasma were isolated in a tabletop centrifuge at
∼1590 g for 15min at room temperature and pooled from 3 mice. The
pooled plasma was stored at 4 °C.
2.2. Lipoprotein measurement and S/L/M-HDL fractions isolation
HDL particles were fractionated as described [17]. Briefly, 450 μL of
pooled plasma was applied to a Superdex 200 gel filtration column (10/
300 GL, GE Healthcare) in an ÄKTA fast protein liquid chromatography
(FPLC) system, and separated at a flow rate of 0.3mL/min in standard
Tris buffer (10mM Tris, 0.15M NaCl, 1 mM EDTA). 48 fractions were
collected (GE Healthcare) and stored at 4 °C.
FPLC fractions were tested for lipid and total protein concentrations
by using Colorimetric kits and bicinchoninic acid (BCA). Protein con-
tent of lipoprotein fractions were quantified by the absorbance at
OD280. Total cholesterol (TC) and triglyceride (TG) levels were assayed
by Colorimetric kits. Phospholipid (PL) levels were assessed by using
enzymatic kits from Wako Diagnostics (Richmond, VA). Fractions 10 to
15 were determined as VLDL by high content of TG, 16 to 22 as LDL by
the lower protein peak, 25 to 36 as HDL by higher PL and TC content,
and 37 to 45 as albumin. HDL fractions were evenly clustered into 3
pools according to particle size, fractions 25 to 28 as large-HDL parti-
cles (L-HDL), 29 to 32 as medium-HDL (M-HDL), and 33 to 36 as small-
HDL (S-HDL). Total protein concentration in small, medium and large
(S/M/L)-HDL fractions were assessed by BCA assay. Total PL, choles-
terol, and TG in S/L/M-HDL fractions were normalized by protein
content in each fraction.
2.3. Mass spectrometry analysis of S/L/M-HDL fractions
The pooled S/L/M-HDL fractions were then purified for PL mea-
surenment by using a calcium silica hydrate (CSH) resin as described
[17]. Briefly, 400 μL each fraction had 45 μg of CSH added, mixed
gently for 30min at room temperature, and pelleted by centrifugation
(∼2200×g for 2min). Supernatant containing lipid-free plasma pro-
teins was removed and the remaining CSH pellet was washed with
50mM ammonium bicarbonate (AB).
These PL containting components of each pooled fraction were then
subjected to mass spectrometry (MS) analysis using a Qstar XL-MS
system [24]. In brief, HDL particles were digested with trypsin while
still bound to the CSH. Sequencing grade trypsin (1.5 μg in 25 μL of
50mM AB) was added to each CSH pellet and incubated at 37 °C
overnight on a rotating plate. To collect the digested peptides, the CSH
was washed with 125 μL of 50mM AB. Eluted peptides were first re-
duced and then carbamidomethylated with dithiothreitol (200mM
30min at 37 °C) and iodoacetamide (800mM 30min at room tem-
perature), respectively. Peptides solutions were then lyophilized to
dryness and stored at −20 °C until analyzed by MS.
Dried peptides were reconstituted in 15 μL of 0.1% formic acid in
water. An Agilent 1100 series auto-sampler/HPLC was used to draw
0.5 μL of sample and inject it onto a C18 reverse phase column (GRACE
150× 0.500mm) where an acetonitrile concentration gradient (5–30%
in water with 0.1% formic acid) was used to elute peptides for online
ESI-MS/MS by a QStar XL mass spectrometer. Column cleaning was
conducted automatically with 2 cycles of a 5–85% acetonitrile gradient
lasting 15min each between runs.
To identify the protein composition of lipid containing particles,
peak lists generated from analysis of each fraction were scanned against
the Swiss-Prot Protein Knowledgebase for Mus musculus (release 2011,
533657 sequences) using Mascot (ver. 2.2.07) and X! Tandem (ver.
2010.12.01.1) search engines. Scaffold software (ver. Scaffold_4.3.4,
Proteome software) was used to validate MS based peptide and protein
identifications. Since equal volumes of sample were applied to the MS
analysis, the relative amount of given protein present in a given fraction
is proportional to the number of special counts in each fraction. This
method provides a semi quantitative abundance pattern across each
fraction as immunological analysis [25]. The MS proteomics data have
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been deposited to the ProteomeXchange Consortium via the PRIDE
partner repository with the dataset identifier PXD011185. It will be-
come accessible via http://www.proteomexchange.org. upon the
manuscript publication.
2.4. Classification of FPLC-MS identified proteins in mouse HDL
Abbreviation and Uniprot ID of MS identified proteins in S/L/M-
HDL were abtained from public databases (Genecards and Uniprot).
Protein was classified according to their biological function described in
Pathcards Pathway Unification Data Base. Because many of the im-
munoglobulins discussed do not have abbreviations in Genecards, we
used their full protein name.
2.5. Comparison of HDL protein abundance between mouse S/L/M-HDL
HDL protein abundance was compared between mouse S/L/M-HDL
particles based on relative abundance of MS identified peptide counts.
A value of 1.0 was assigned to the highest peptide count of each specific
protein in each HDL fractions. Peptide counts for other proteins were
scaled accordingly and presented as Heat map. Next, we identified
overlapped proteins in three S/L/M-HDL subclass and presented as
Venn-diagram. Finally, fold value of peptide counts in L-HDL was cal-
culated by dividing that in S-HDL. Positive numbers describe the fold
changes of increased proteins in L-HDL. Negative numbers describe the
fold changes of decreased proteins which and was derived by dividing
negative one (−1) by the fold value.
2.6. Identification of HDL proteins dynamic change in mouse S/L/M-HDL
HDL protein dynamic changes (increase or decrease during HDL
maturation) from S-HDL to L-HDL were grouped by database-defined
biological functions and graphed on their relative abundance value.
2.7. Identification of replicated proteins in human and mouse HDL and their
dynamic changes
Replicated proteins in human and mouse HDL were identified by
comparing our mouse HDL proteomics data with published HDL pro-
teomics data of human and mouse available in PubMed from 2010 to
2015. Among 276 reported human HDL proteins, only 93 were reported
2 times or more and were selected for analysis. There were only 2
mouse HDL proteomics reported during this period of time, with only
19 out of 111 replicated in both publications.
Dynamic changes of the identified replicated proteins in human and
mouse HDL were grouped by whether they increased or decreased
during HDL maturation, and graphed on their relative abundance value.
2.8. Identification and comparison of ingenuity pathways and disease/bio-
functions of identified S/M/L-HDL proteins (IPA software)
In order to explore HDL functional diversity derived from HDL
protein dynamic changes, we identified ingenuity pathways and dis-
ease/bio-functions of the 51 identified HDL protein in S/L/M-HDL
using Ingenuity Pathway Analysis (IPA) software (www.ingenuity.
com).
The significance of identified pathways and disease/bio-functions
were evaluated by p-value which described the significane of individual
pathways over others in each HDL fraction. The number of HDL pro-
teins over the total previously identified proteins are described as
overlaps with percentage. Overlap describes the number of identified
HDL protein overlaps with the listed pathway molecules. The sig-
nificance comparison of Ingenuity pathways and disease/bio-functions
between the three HDL fractions was calculated as p value using IPA
software.
2.9. Identification of top scored networks and related diseases/bio-functions
of S/L/M-HDL proteins (IPA software)
To investigate whether S/L/M-HDL proteins were related to the
diversity bio-functions of HDL in RCT, predicted networks of S/L/M-
HDL proteins were identified via their interconnected molecules using
IPA software. IPA score are calculated using the IPA algorithm.
Network-related diseases/bio-functions were solicited also using IPA
software.
2.10. Experimental design and statistical rationale
For the investigation of HDL cardioprotective functional signatures,
in S/M/L HDL fractions respectively, WT mouse plasma was applied to
FPLC, and divided into 47 fractions totally. HDL particles characterized
by their high PL content were enriched in fractions 25–36. In order to
improve methodological sensitivity, we pooled three plasma samples
together to decrease coefficient of variation of the mean, rather than
applying technical replicates. We used 3 replicates for statistics in li-
poprotein profile and L/M/S-HDL subclass characterization. Results are
expressed as the mean ± SEM. Statistical comparison of single para-
meters between two groups was performed by independent t-test. A
probability value p < 0.05 was considered to be significant. We further
evenly divided the HDL fractions into three subclasses according to
particle size, fractions 25–28 as large particles, 29–32 as medium, and
33–36 as small, to properly reflect the average/weighted average and
more decrease the variation in each of the S/M/L HDL fractions.
2.11. Quantifications
Experimental data was presented as means ± SEM. Differences of
statistical significance were determined by one-way analysis of variance
(ANOVA) followed by Bonferroni's post hoc test. Statistical significance
was defined as a two-tailed probability of less than 0.05. The sig-
nificance of identified pathway and disease/bio-function analysis be-
tween three fractions was calculated as p value using IPA software.
3. Results
3.1. Lipoprotein profile and S/L/M-HDL fraction characterization
We determined the content of protein, PL, TC and TG by FPLC
fractionation of pooled plasma from male C57/B6 mice (Fig. 1A). We
defined the HDL particles for fractions 25–36 based on their high
content of PL and TC (Fig. 1C/D), VLDL particles for fractions 10–15
based on their high TG content (Fig. 1E), and distinguished LDL particle
for fractions 16–22 (Fig. 1B).
HDL fractions were divided evenly and grouped as L-HDL (fractions
25–28), M-HDL (fractions 29–32) and S-HDL (fractions 33–36). Protein
concentration was higher in S-HDL (1.54 ± 0.10mg/mL), lower in M-
HDL (0.36 ± 0.12mg/mL), and much lower in L-HDL
(0.07 ± 0.01mg/mL)(Fig. 1F). Relative concentration of PL, TC and
TG, normalized by protein concentration, appeared to be the lowest in
S-HDL (2.18 ± 1.12, 1.13 ± 1.03 and 0.20 ± 0.18 μg/mg), relatively
high in L-HDL (24.16 ± 1.14, 13.34 ± 0.73 and 1.52 ± 0.13 μg/mg),
and the highest in M-HDL (33.35 ± 2.01, 19.26 ± 2.07 and
1.93 ± 0.10 μg/mg) (Fig. 1G/H/I).
3.2. Proteins identified in mouse L/M/S-HDL particles and their
representative biological functions
We detected totally 51 proteins in all S/M/L-HDL subclasses by MS
analysis and present the protein name, abbreviation and UniProt ID
from public databases in Table 1A. We divided these 51 proteins into 4
biological functional groups. Group 1 lipid metabolism includes 5
proteins (ApoA1, ApoA2, ApoA4, ApoC3, and ApoE). Group 2 contains
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25 immune response proteins, including 3 subgroups such as comple-
ment (10 proteins; C3, C4B, C5, C8A, C8B, C8G, CFB, CFH, CFI, and
Clu), immunoglobulins (7 proteins; Igcab, Igfals, Igg2B, Ighg3, Igkc,
Igγ-1, and Lac-1), and inflammation (7 proteins; Hla-B, Ambp, Pon1,
Saa4, ItiH1, ItiH3, and ItiH4). Group 3 coagulation (7 proteins; F2, F10,
Klkb1, Kng, Serpina10, Serpinf2, and Serping1). Group 4 has 14 other
proteins (Ahsg, Alb, CpN1, CpN2, Afm, EGFR, Fn1, Gpld1, CP, Lifr,
Mug1, and Vtn)(Table 1B).
3.3. Identification of protein overlaps in mouse HDL subclasses
We presented abundance of MS identified protein from S/M/L-HDL
subclasses based on peptide counts in Fig. 2A/B. S-HDL contains 39
proteins, and 26 of these have the highest abundance index of 1.0. M-
HDL contains 27 proteins, of which 10 have abundance index of 1.0. L-
HDL contains 29 proteins, of which 15 have abundance index of 1.0.
During the maturation of HDL particles, 18 of 39 S-HLD proteins are
absent in M-HDL, 6 more are absent in L-HDL. The M-HDL subclass
recruited 9 new proteins, of which 3 are absent in L-HDL. The L-HDL
subclass also recruited 9 new proteins. We identified 11 common HDL
proteins in all S/M/L-HDL fractions, including Ambp, ApoA1, ApoA2,
ApoA4, ApoE, C3, C4B, Clu, Kng1, Saa4, and Mug1 (Figure 2B), 7 L-
HDL-specific proteins (CFH, CpN1, CpN2, Fn1, Gpld1, Hba, and Hla-B),
3M-HDL-only proteins (ItiH3, Serpina10,and Serping1) and 16 unique
S-HDL proteins (Afm, Ahsg, C8A, C8B, C8G, CFB, CFI, F10, F2, Hpx,
Igfals, Ighg3, Igγ-1, Lac1, Serpinf2,and Vtn) (Fig. 2A/B).
We calculated fold changes by comparing that in L-HDL vs S-HDL
(Fig. 2C). ApoE was increased by 39.48-fold, Mug1 by 15.23-fold and
Ambp by 12.01-fold. Thirteen proteins were only presented in L-HDL
(∞). In contrast, C3 was reduced by 57.63-fold, Clu by 41.49-fold and
ApoA1 by 1.55-fold in L-HDL. Twenty-one proteins were absent only in
L-HDL(-∞).
3.4. Dynamic protein distribution in mouse HDL subclasses by biological
function groups
HDL protein dynamic were characterized by 4 biological function
groups defined in Table 1B. Fig. 3-A/B/C/D each present one group and
divided into increased or decreased from S-HDL towards the maturation
to M/L-HDL. Among lipid metabolism-related proteins, ApoE was in-
creased, ApoA1/2 and ApoC3 were nearly steadily expressed, and
ApoA4 was slightly decreased in L-HDL (Fig. 3A). Immune response-
related proteins were divided into 3 subgroups. The complement pro-
teins C5 and CFH were increased, while C3, C4B, C8A, C8B, C8G, CFB,
CFI and Clu were decreased in L-HDL (Fig. 3B1). The inflammation-
related proteins Ambp, Hla-B, ItiH1, ItiH2, and Pon1 were increased,
but ItiH3, ItiH4, and Saa4 were decreased (Fig. 3B2). Interestingly, all
identified immunoglobulin proteins were decreased in L-HDL
(Fig. 3B3). The coagulation related proteins Klkb1, Kng, Serpina10 and
Serping1 exhibited an increased pattern, but Serpinf2, F10 and F2 were
Fig. 1. Lipoprotein profile and L/M/S-HDL subclass characterization of mouse plasma. Blood was collected from male C57BL/6J mice at 14–16 weeks of age.
Pooled plasma from 3 mice was applied to a ÄKTA FPLC system for lipoprotein fractionation. Forty-eight fractions were collected and further assessed for phos-
pholipid, cholesterol, and triglyceride concentrations using biochemical kits from Wako. Protein content was quantified by the absorbance at OD280. Fractions 10 to
15 were determined as VLDL by the peak of triglyceride, 16 to 22 as LDL by the peak of protein, 25 to 36 as HDL by the peak of phospholipid, 37 to 45 as albumin.
Fractions 25 to 28 were pooled as large-HDL particles (L-HDL), 29 to 32 as medium-HDL (M-HDL), and 33 to 36 as small-HDL (S-HDL). (A) Model of lipoprotein
fractionation and lipid/protein analysis (FPLC-MS). (B) Protein. (C) Phospholipid. (D) Total cholesterol. (E) Triglyceride. Protein, phospholipid, total
cholesterol and triglyceride profiles were established by biochemical assessment in 48 fractions. (F) HDL protein. Protein concentrations of pooled L/M/S-HDL
fractions were assessed by BCA assay. (G) HDL phospholipid. (H) HDL total cholesterol. (I) HDL triglyceride. Phospholipid, total cholesterol and triglyceride
content of pooled L/M/S-HDL fractions were assessed and normalized by HDL protein concentration. HDL, high density lipoprotein; LDL, low density lipoprotein;
VLDL, very low density lipoprotein. BCA, bicinchoninic acid. *p < 0.05 compared with L-HDL, #p < 0.05 compared with M-HDL.
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decreased in L-HDL (Fig. 3C). Finally, in the other type protein group,
CpN1, CpN2, Fn1, Gpld1, Hba, Lifr and Mug1 were increased, whereas
Ahsg, CP, EGFR, Hpx, Vtn and Afm were decreased in L-HDL (Fig. 3D).
3.5. Model of protein composition change during HDL biosynthesis/
maturation
We established a model to describe transition points when HDL
proteins join or leave HDL subclasses during HDL biosynthesis/ma-
turation. We found that all S/M/L-HDL contains ApoA1/2/4 and ApoC3
proteins, and ApoE joined only in L-HDL. From S-HDL-to M-HDL, 17
proteins departured 11 joined. From M-HDL to L-HDL, 10 proteins
departured M-HDL and 8 joined. Furthermore, we distinguished func-
tions of each S/M/L-HDL subclass based on that of their protein com-
ponents. S-HDL proteins are primarily associated with cholesterol ef-
flux, the immune response, and amino acid metabolism. M-HDL
proteins are more closely associated with cholesterol efflux, the
immune response/anti-inflammation, and antioxidation/antic-
oagulation. L-HDL proteins are more closely associated with cholesterol
efflux/clearance, the immune response/anti-inflammation, and anti-
oxidation (Fig. 3E).
3.6. Identification of replicated proteins in human and mouse HDL
We compared our data with published HDL proteomics datasets (10
human HDL and 2 mouse HDL proteomics) (Fig. 4A/B). Among 276
proteins identified in human HDL, we identified 93 replicated proteins
(reported≥ 2 times). Among 111 mouse HDL proteins identified by
others, 19 are replicated (details in Supplemental Table 2). Finally, we
identified 12 replicated proteins among all published humans/mouse
and our mouse HDL proteins (replicated ≥3 times). We presented the
distribution pattern of these 12 replicated HDL proteins in S/M/L-HDL
subclasses in Fig. 4C. During HDL maturation, Among these 12 re-
plicated HDL proteins, three proteins (PON1, C5 and ApoE) increased, 4
Table 1
Proteins identified in mouse L/M/S-HDL particles and their representative biological functions. Pooled mouse plasma fractionated using an ÄKTA FPLC
system. Large, medium, small HDL particles were collected as described in Fig. 1 and subjected to proteomic analysis. (A) Identified HDL proteins; 51 proteins
were identified in HDL particles by MS and listed. The abbreviation and Uniprot ID of the proteins were obtained from public databases (Genecards and Uniprot).
(B) Biological function of HDL proteins; 51 identified HDL proteins are presented by four relevant biological function groups based on classification in the
literature and multiple databases as described in Material and Methods.
A proteins identified in mouse L/M/S-HDL particles(51 proteins, FPLC-MS)
Protein name Abbreviation Uniprot ID Protein name Abbraviation Uniprot ID Protein name Abbraviation Uniprot ID
Afamin Afm O89020 Epidermal GF-R EGFR Q01279 Inter- α trypsin inhibitor
chain H2
ItiH2 Q61703
α-2-HS-glycoprotein Ahsg P29699 Coagulation factor X F10 O88947
Albumin Alb P07724 Prothrombin F2 P19221 Inter- α trypsin inhibitor
chain H3
ItiH3 Q61704
α-1-microglobulin Am bp Q07456 Fibronectin Fn1 P11276
Apolipoprotein A-I ApoA1 Q00623 Phosphatidylinositol-glycan- specific
phospholipase
Gpldl O70362 Inter- α trypsin inhibitor
chain H4
ItiH4 A6X935
Apolipoprotein A-II ApoA2 P09813 Hemoglobin subunit-α
H2 class I
Hba P01942
Apolipoprotein A-IV ApoA4 P06728 Histocompatibility antigen,Q10 α chain Hla-B P01898 kallikrein Klkbl P26262
Apolipoprotein C-III ApoC3 P33622 Hemopexin Hpx Q91X72 Kininogen-1 Kng 008677
Apolipoprotein E ApoE P08226 Ig-γ-2A chain C region secreted form Igcab P01864 Ig-λ
−1 chain C region
Lac1 P01843
Complement C3 C3 P01027 Insulin-like GF binding protein complex
acid labile subunit
Igfals P70389 Leukemia inhibitory factor
receptor
Lifr P42703
Complement C4–B C4B P01029 Ig-γ-2B chain C region lgg2B P01867
Complement C5 C5 P06684 Ig-γ-3 chain C region Ighg3 P03987 Murinoglobulin-1 Mug1 P28665
Complement C8A C8A Q8K182 Ig-κ chain C region IgkC P01837 Paraoxonase Poni P52430
Complement C8 C8B Q8BH35 Ig γ-1 chain C region, membrane bound
form
Igγ −1 P01869 Amyloid A-4 Saa4 P31532
Complement C8G C8G Q8VCG4 Inter- α trypsin inhibitor chain H1 ItiH1 Q61702 Protein Z-dependent protease
inhibitor
SerpinalO Q8R121
Complement factor B CFB P04186
Complement factor H CFH P06909 A-2-antiplasmin Serpinf 2 Q61247
Complement factor I CFI Q61129 Plasma protease C1 inhibitor Serpingl P97290
Clusterin Clu Q06890
Ceruloplasmin CP Q61147 Vitronectin Vtn P29788
Carboxypeptidase N catalytic
chain
CpN1 Q9JJN5
Carboxypeptidase N subunit 2 CpN2 Q9DBB9
B Biological functions of identified mouse L/M/S-HDL proteins
1. Lipid Metabolism (5 proteins) ApoA1, ApoA2, ApoA4, ApoC3, ApoE
2. Immune Response (25 proteins)
Compliment C3, C4B, C5, C8A, C8B, C8G
CFB, CFH, CFI, Clu
Immunoglobulin Igcab
Igfals, lgg2B, Ighg3
Igkc, lgγ-1, Lac-1
Inflammation Hla-B, Ambp, ItiH1, ItiH2,
ItiH3, ItiH4, Pon1, Saa4
3. Coagulation
(7 proteins)
F2, F10, Klkbl, Kng
Serpina10, Serpinf2
Serping1
4. Other
(14 proteins)
Ahsg, Alb, CpN1, CpN2, Afm
EGFR, Fn1, Gpldl, Hba,
CP, Hpx, Lifr, Mug1, Vtn
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proteins (ApoA1, ApoA2, ApoC3, and KNG1) nearly steadily expressed,
and 5 proteins (C3, SAA4, VTN, CP, and ApoA4) largely reduced.
3.7. Identification of ingenuity pathways and disease/bio-functions of HDL
subclasses and significance comparison
Using pathway identification strategies and IPA software, we de-
termined Ingenuity pathways and disease/bio-functions related to the
51 mouse HDL proteins we identified in this study. S-HDL fractions
were most likely related to the regulation of 3 top Ingenuity pathways
(LXR/RXR activation, FXR/RXR activation, and acute phase response)
(Fig. 5B) and 5 top bio-function groups (complement activation, organ
inflammation, hemolysis, cytolysis and inflammation)(Fig. 5C). Among
the 39 identified mouse S-HDL proteins, 35.9–38.5% and 20.5–46.2%
are involved in these Ingenuity pathways and disease/bio-function
groups, respectively. M-HDL fractions were most likely related to 3
Ingenuity pathways (LXR/RXR activation, FXR/RXR activation and
acute phase response) and 5bio-function groups (complement activa-
tion, inflammation, acute coronary syndrome, PL efflux and myocardial
infarction), involving 40.7–55.6% and 25.9–55.6% of the identified M-
HDL proteins, respectively. L-HDL fractions are most likely related to 3
Ingenuity pathways (LXR/RXR activation, FXR/RXR activation and
acute phase response) and 5 top bio-function groups (complement ac-
tivation, cholesterol efflux/metabolism, PL efflux, vascular disease and
lipid homeostasis/transport), involving 34.5–41.4% and 17.2–44.8% of
the identified L-HDL proteins, respectively. Via significance compar-
ison, we found that S-HDL proteins favor LXR/RXR and FXR/RXR
activation, acute phase response, complement system, coagulation
system, inflammation and lipid metabolism, and L-HDL proteins were
more closely related to clathrin-mediated endocytosis, atherosclerosis,
macrophage IL-12 production and cholesterol efflux (Fig. 5D/E).
3.8. Network identification of HDL proteins
We further identified connective networks for each S/M/L-HDL
fraction (Fig. 6A/B). We list 3 top S-HDL networks. The first one is for
humoral immune/inflammatory responses/carbohydrate metabolism.
The second one is for cellular assembly/organization/tissue develop-
ment/cellular function and maintenance. The first S-HDL network in-
volves 22 our identified protein (56.4% of all network proteins, with 59
IPA score) including the inflammatory molecules Saa, ItiH4, comple-
ment C3 and CFB (Fig. 6D). Among the 3 top M-HDL networks, the first
one is for developmental & hereditary disorders/immunological dis-
ease. The second one is for cell survival/cellular compromise and de-
velopment. The first M-HDL network involves 21 our identified protein
(77.8% of all network proteins, with 59 IPA score) including the thiol
protease inhibitor Kng1, the collagen biosynthesis enzyme Klkb1, C3
and the antioxidant Pon1 (Fig. 6E). Among the 3 L-HDL networks, the
first one is for cell survival/connective tissue disorders/hematological
disease. The second one is for lipid metabolism/small molecule bio-
chemistry/drug metabolism. The first L-HDL network involves 21 our
identified protein (72.4% of all network proteins, with 59 IPA score)
including ApoA1, ApoA2, ApoA4, and Pon1 (Fig. 6F).
Fig. 2. Identification of protein overlaps in mouse HDL
subclasses. Pooled mouse plasma was fractionated using an
ÄKTA FPLC system. Large, medium, small HDL subclasses
were collected as described in Fig. 1 and subjected to pro-
teomic analysis using a Qstar XL-MS system. 51 proteins
were identified in HDL particles and abbreviated according
to Genecards website. (A) Heat map of relative protein
abundance in HDL particles. Relative abundance of each
identified protein in HDL particles were described by pep-
tide count, determined by MS. A value of 1.0 was assigned to
the highest peptide count of the specific protein in three S/
M/L-HDL subclasses. Peptide counts for other proteins were
scaled accordingly. The highest values are colored red and
gradually changed to yellow for the lower values. Green
indicates no peptide was identified in that particular HDL
fraction. (B) Protein overlaps in HDL particle; Venn-dia-
gram describes the presence of identified protein in HDL
particles (39 in S-HDL, 27 in M-HDL, and 29 in L-HDL). 11
proteins overlap in all S/M/L-HDL fractions and are listed as
common HDL proteins. (C) Fold-change of protein peptide
counts in L-HDL; Fold change of each protein in L-HDL was
calculated with dividing its peptide count in L-HDL by that
in S-HDL. Positive numbers describe the fold changes of
increased proteins in L-HDL. Negative numbers describe the
fold changes of decreased proteins derived from dividing
negative one (−1) by the fold value. Infinity symbol “∞”
indicates protein present in L-HDL but absent in S-HDL.,
whereas, “-∞” indicates protein absent in L-HDL but present
in S-HDL. Protein name abbreviation are explained in
Table 1A. (For interpretation of the references to color in
this figure legend, the reader is referred to the Web version
of this article.)
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Fig. 3. Dynamic protein distribution in mouse HDL subclasses by biological function groups and model of protein composition change during HDL
biosynthesis/maturation. HDL fractions (S/M/L) were collected from FPLC purification as described in Fig. 1. Proteins in each HDL fraction were identified by
Qstar XL-MS analysis as describing in Fig. 2. Relative abundance of each identified protein in HDL particles were described by peptide count, determined by MS. A
value of 1.0 was assigned to the highest peptide count of the specific protein in three S/M/L-HDL fractions. Identified HDL proteins were grouped by the biological
function as describing in Table 1 and classified as increased and decreased groups. Protein dynamic changes are presented as relative peptide count curves. (A) Lipid
metabolism. (B) Immune response; B1, Complement proteins, B2, Inflammatory protein, B3, Immunoglobin proteins. (C) Coagulation proteins. (D) Other
types. (E) Model of protein composition change during HDL biosynthesis/maturation. Flow chat describes transition points when HDL proteins join or
departure from HDL subgroups during HDL biosynthesis/maturation. Protein names highlighted in red are those emphasized in the session of discussion. Protein
name abbreviation are explained in Table 1A. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this
article.)
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4. Discussion
During the process of RCT, HDL particles gradually mature and
enlarge. HDL comprises a multitude of discrete proteins and differ in
their composition, proteome and functional properties. In this study, we
developed a strategy to classify HDL particles based on their size and to
characterize the protein composition of these HDL subclasses. We
identified 51 mouse HDL proteins and discovered 12 of them are re-
plicated in previously published human and mouse HDL proteomes. We
developed a model of protein composition change during HDL ma-
turation and defined essential functions for all HDL particles as
cholesterol efflux and immune response. Specifically for each subclass
we determined special function of amino acid metabolism for S-HDL,
anti-coagulation for M-HDL, and cholesterial clearance for L-HDL. We
proposed that Pon1 is recruited into M/L-HDL to provide its anti-
oxidatiove function. ApoE is incorporated into L-HDL to optimize its
cholesterial clearance function.
We believe FPLC separation is a more effective method for HDL
proteome study because FPLC isolation does not alter the analyzed
substance. This retains most HDL protein components that might con-
tribute to their heterogeneous functions. A traditional HDL isolation
method is density gradient ultracentrifugation, which separates HDL
Fig. 4. Identification of replicated proteins in human and mouse HDL. Reported HDL proteomics data was acquired from PubMed database. 14 human and
2 mouse HDL proteomics data were reported (from 2010 to 2015, details in Supplement Table 2), which were compared to our mouse HDL proteome. (A) Iden-
tification of replicated HDL protein. HDL proteins were presented by number of reported/publication times. 94 replicated human HDL proteins (published≥ 2
times among 275 reported human HDL proteins), 72 replicated mouse HDL proteins (published≥ 2 times among 111 reported mouse HDL proteins or replicated with
our data) are presented. 12 replicated HDL proteins are identified (replicated≥ 3 times in human and mouse proteomics) and framed in dash line. (B) Strategy for
the identification of 12 replicated HDL proteins. (C) Dynamic distribution of 12 replicated HDL proteins; Relative abundance of each identified protein in HDL
particles were described by relative peptide count determined by MS. A value of 1.0 was assigned to the highest peptide count in three S/M/L-HDL subclasses. Protein
dynamic changes are expressed as peptide count curves. Identified HDL proteins were classified as increased, decreased and steadily expressed groups. Protein name
abbreviation are explained in Table 1A. Standard abbreviations of HDL proteins were obtained from public databases (Genecards and Uniprot).
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subfractions based on the buoyancy profile of lipoproteins using high-
salt solutions and high centrifugal force. These extreme conditions in-
crease the likelihood of denaturing the structural and chemical prop-
erties of HDL and removing associated proteins [26]. The drawback of
the FPLC technique is the tendency towards fraction contamination
with other plasma particles of similar sizes to that of HDL. For example,
albumin overlapped with S-HDL and interfered with its fragmentation
(Fig. 1B). This interference was resolved by PL and TC quantification,
(caption on next page)
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Fig. 5. Identification of Ingenuity pathways & disease/bio-functions of HDL proteins and significance comparison (IPA software). 51 HDL proteins were
identified by FPLC purification and MS analysis as described in Fig. 1 and Table 1. The abbreviation and Uniprot ID of these HDL proteins were obtained from public
databases (Genecards and Uniprot) and used for the identification of Ingenuity pathways and disease/bio-functions (www.ingenuity.com). (A) Strategy for pathway
& function analysis of HDL proteins. (B) Top 3 ingenuity pathways of S/M/L-HDL proteins. (C) Top 5 disease/bio-functions of S/M/L HDL proteins. The top
3 Ingenuity canonical pathways and top 5 disease/bio-functions of L/M/S-HDL particles were identified. The significance of identified pathways and disease/bio-
functions were evaluated by p-value which describes the significance of individual pathway over others in each HDL fraction. Overlaps describe the numbers and
percentage of identified HDL proteins in the previously identified pathway proteins. (D) Heat map of significance comparison of ingenuity pathways. (E) Heat
map of significance comparison of disease/bio-functions. The significance comparison of Ingenuity pathways and disease/bio-functions between three HDL
fractions was calculated as P value using IPA software and presented in the heat map. Blue color represents the highest significance (the smallest p value) of the
identified pathway among three HDL fractions. White color represents the lowest significance (the largest p value) among three fractions. Abbreviations: AD,
Alzheimer's disease; defi., deficiency; HSC, hematopoiesis; MΦ, macrophage; NO, nitric oxide; R, Receptor; ROS, reactive oxygen species; SC, stem cell; TC, targeted
cell, T1DM, type 1 diabetes mellitus. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Fig. 6. Network identification of HDL proteins (IPA software). (A) Strategy of network identification. 51 HDL proteins (39 in S-HDL, 27 in M-HDL, and 29 in L-
HDL) were identified in mouse plasma by FPLC purification and MS analysis as describing in Fig. 1 and Table 1 and used for network analyzing by IPA software
(www.ingenuity.com). Predicted networks and score are calculated using IPA algorithm. Each connection represents known relationships between the molecules
found in the Ingenuity knowledge base. (B) Top 3 networks for each HDL population. The top 3 scored networks and their associated diseases/bio-functions of L/
M/S-HDL are presented. (C) Molecular property of network proteins. (D) S-HDL top network. (E) M-HDL top network. (F). L-HDL top network. The highest
scored networks for S/M/L-HDL subclasses are presented. Blue lines indicate direct interactions of 2 molecules. Green lines indicate indirect interactions. The
symbols describe the property of the molecules and explained in C. Abbreviations for identified HDL proteins are explained in Table 1A. (For interpretation of the
references to color in this figure legend, the reader is referred to the Web version of this article.)
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which precisely distinguished HDL (Fig. 1C/D). Another special ad-
vantage of the FPLC technique is the ability to further precisely frac-
tionate HDL subgroups, which allows for accurate quantitative che-
mical and molecular analysis of our fractions. Using these advanced
technologies in combination with FPLC and lipid chemical analysis, we
obtained well-separated HDL fractions and, for the first time, analyzed
the proteome and major lipid components of pooled S/M/L-HDL sub-
populations. We found that protein concentration in L/M-HDL was 6-
fold lower than those in S-HDL (0.1–0.4–1.4mg/ml) (Fig. 1F). PL, TC
and TG were enriched by approximately 7-, 10- and 20-fold in L/M-HDL
over S-HDL (25–34 to 3 μg/mg, 14–20 to 3 μg/mg, 1.5–1.7 to 0.25 μg/
mg) (Fig. 1G/H/I). These data provided quantitative information to
support the theory of increased lipid and decreased protein content
during HDL maturation [27]. We identified 10/27 different proteins in
L/M-HDL and 39 proteins in S-HDL(Fig. 2), suggesting that the high
protein content in S-HDL is, at least in part, related to its abundance of
protein constituents. It is likely that various protein constituents in S-
HDL determine its diverse functions, described as follows.
Our mouse HDL subclass proteome on FPLC-derived S/M/L-HDL
subclasses displayed differential composition and dynamic change of
protein components during HDL maturation; leading us to propose that
HDL protein component determines the diversed biological function of
diefferent HDL subclasses. We found that, in general, the 39 S-HDL
proteins modulate cholesterol efflux, immune response and amino acid
metabolism. M-HDL and L-HDL contain fewer proteins (27 and 29) and
carry out anti-inflammation and antioxidation roles, in addition to
cholesterol efflux and immune responses. M-HDL is specifically asso-
ciated with anticoagulation function. These novel findings suggest that
differential protein composition and dynamic changes in the HDL
subpopulation may better reflect HDL functions than HDL-C levels.
We identified 10 complement proteins in HDL fractions. C5 and CFH
had very low levels in S-HDL but become highly expressed in L-HDL. In
contrast, the other 8 complement proteins (C3, C4B, C8A, C8B, C8G,
CFB, CFI and Clu) were highly expressed in S-HDL but almost dis-
appeared in L-HDL. HDL has been recognized as a carrier of comple-
ment proteins in humans and has been shown to contain C1q, C1s, C2,
C3, C4, C5, C9, FB, FH, and C1–INH [17,28,29]. As a part of the innate
immune system, complement activation results in the formation of the
cell-killing membrane attack complex [30]. Over 30 different proteins
have been implicated in the complement pathway. At least 17 of these
proteins have been found to bind to HDL, supporting the concept of
HDL involvement in complement regulation [31]. We found that CFH, a
complement inhibitor protein, is greatly increased in L-HDL (Fig. 3B1).
The enrichment of CFH in L-HDL may explain the ability of HDL to
prevent the organization of complement membrane attack complex
[32,33] and to suppress inflammation. The 8 S-HDL enriched comple-
ment proteins (Fig. 3B1) may contribute to the immune/inflammatory
function of S-HDL suggested in this study. It is likely that S-HDL par-
ticipates in complement activation, phagocytosis, pathogen elimination
and the inflammatory response. Complement system activation has
been linked to CVD and metabolic complications, potentially via its
cytolysis effect [32]. Studies in our laboratory are currently being
performed to test whether complement protein-enriched S-HDL is
harmful to biological systems.
Among inflammation-related proteins (Fig. 3B2), we found that
Ambp, ItiH1, and ItiH2 were increased in M/L-HDL, whereas ItiH3 and
ItiH4 were reduced. These proteins are implicated in adhesion, ligand
binding/uptake by scavenger receptors and may be responsible for the
interaction between M/L-HDL and cells independent of apolipopro-
teins. Importantly, Pon1, a well-characterized antioxidation protein,
appeared only in M/L-HDL. Pon1 is known for its HDL-associated an-
tioxidant capacity [34]. Reduced Pon1 activity is associated with in-
creased oxidative stress and CVD in humans and with atherogenesis in
mice [28,35,36]. This finding suggests that HDL antioxidant capacity
34is present only in M/L-HDL, not in S-HDL. In addition, we identified
an abundance of Saa4 in S-HDL only. Since Saa4 is an acute phase
protein associated with folate metabolism [37], which is a key re-
methylation pathway for methionine-homocysteine metabolism, S-HDL
may participate in regulating amino acid and methylation metabolism.
We found 7 immunoglobulins favorably expressed in S-HDL, re-
duced in M-HDL, and absent in L-HDL (Fig. 3B3). The 8 S-HDL-enriched
complement proteins exhibited a similar pattern. This further supports
the role of S-HDL in complement activation and innate and adaptive
immune regulation. We identified 7 HDL-associated coagulation pro-
teins, including 2 pro-coagulating proteins (F10 and F2) and 5 antic-
oagulating proteins (Klkb1, Kng1 and Serpina1/2/10) (Fig. 3C). All
proteins were present at relatively low concentrations in L-HDL. This
insinuates that HDL particles, or at least L-HDL particles, do not play
important roles in coagulation and thrombotic regulation. We identified
13 HDL-associated proteins with diverse functions and classified them
as other types of proteins (Fig. 3D). This heterogeneity of diverse pro-
teins in HDL subfractions suggests alternative functions for different
HDL subfractions and highlights the need for further molecular studies.
We presented a model for HDL protein exchange during HDL bio-
synthesis in Fig. 3E and summarized 3 important major features for
mouse HDL protein dynamic changes. 1) All HDL subfractions contain
ApoA1/A2/A4, while only L-HDL contains ApoE. 2) All activating
complement proteins are present in S-HDL, but the inhibitory comple-
ment protein CFH is expressed only in L-HDL. 3) Pon1 is present in M-
HDL and L-HDL. It is known that ApoE mediates cholesterol liver up-
take via the LDL receptor and suppresses the TC- and MC-related in-
flammation response [38,39], consistent with previously reported data
showing the lack of functional HDL in ApoE knockout mice.
We believe that HDL protein dynamic changes determine the het-
erogeneous functions of HDL subpopulations. Considering the overall
protein dynamic changes in S/M/L-HDL, we proposed three major
functions for each HDL subpopulation. The S-HDL fraction mostly
regulates cholesterol efflux, the immune response and amino acid me-
tabolism. The M-HDL fraction maintains cholesterol efflux and immune
response functions and shows new antioxidation and anticoagulation
functions, attributable to the incorporation of Pon1 and the antic-
oagulation proteins Klkb1, Serpina10, Kng, and Serping1. L-HDL is
likely the most protective HDL population. It remains as powerful as M-
HDL in cholesterol efflux and antioxidation but shows enhanced func-
tions in cholesterol liver uptake and anti-inflammation, mostly due to
the dominant expression of the ApoE, CFH and Pon1 proteins. This is
consistent with knowledge of the antioxidative and anti-inflammatory
functions of Pon1, the complement suppression functions of CFH, and
the cholesterol liver uptake and anti-inflammatory functions of ApoE
[38,40–42]. Our findings emphasize three major functions determined
by HDL proteins: lipid transport, immune regulation and antioxidation.
Our data provide evidence of HDL heterogeneity in protein composition
and a connection with the biological functions of HDL subfractions of
different sizes. Studies in our laboratory are undergoing to validate the
biological effects of these different HDL subclasses.
We compared our findings with a few representative HDL proteomic
studies [17,23,43–51] (Supplementary Table 2) and identified 12 re-
plicated proteins in human and mouse HDL that overlapped with our
proteomics results and were reported at least twice in previous HDL
proteomic studies (Fig. 4A/B). Our HDL subclass proteomic dataset is
the first used to evaluate structural and functional connections and
contributions to HDL heterogeneity using replicated HDL proteins in
both humans and mice. We found that the replicated HDL proteins
PON1, C5 and ApoE increased during HDL maturation, which largely
determines the antioxidation, anti-inflammation and cholesterol clear-
ance functions acquired during HDL biosynthesis in both humans and
mice (Fig. 4C). Importantly, ApoA1, ApoA2 and ApoC3 were steadily
expressed in all HDL subclasses, which is critical for maintaining es-
sential cholesterol efflux functions for all HDL populations. The func-
tional implications of C3, Saa4, Vtn, CP and ApoA4, which were gra-
dually reduced during HDL maturation, require further analysis. Our
study aimed to classify the similarity between mouse and human HDL
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proteome and provided rationale for using mouse model to study HDL
proteomics and lipoproteomics in human disease. Research to in-
vestigate human HDL protein dynamics in HDL subclasses and in dis-
ease conditions are on-going in our laboratory, and will be published in
separate manuscripts in the near future.
Our Ingenuity pathway analysis described 3 top pathways (LXR/
RXR activation, FXR/RXR activation, and acute phase response)
(p≤7.94E-09) that were similarly present in all three HDL subfractions
(Fig. 5B) and 5 top disease/bio-functions differentially related to S/M/
L-HDL subclasses (Fig. 5C). Our findings highlighted the functions of
HDL subclasses, especially S-HDL, in LXR/RXR and FXR/RXR activa-
tion, suggesting a novel function of HDL in the trans-activation of lipid
metabolism and cholesterol to bile acid catabolism. The HDL acute
phase response pathway is most likely mediated by the complement
system, since we identified 10 complement proteins as mouse HDL
constituents. Complement activation is the fourth pathway and the first
disease function of HDL identified by Ingenuity pathway analysis
(Fig. 5D/E).
In this study, we used male mice to eliminate the influence of sex
steroid. It is established that lower estrogen levels is associated with
higher morbidity of coronary heart disease and lower HDL-C levels in
human [52,53]. Gender effect on HDL subclass was also reported. Males
have lower HDL2-C and HDL3-C subtraction [55]. Greater declines in
estrogen E2 were associated with large increases in S-HDL-PIMA and
reductions in M-HDL-PIMA in healthy women tansitioning through
Menopause [56]. However, information regarding gender effect on HDL
proteomics is not currently not available. It is likely that sex steroid
effect HDL proteomics and function, which is an interesting topic for
future studies.
In conclusion, our current study provided the first HDL subclass
proteomics. We identified 51 proteins in three mouse S/M/L-HDL
subclasses, and characterized their dynamic changes during HDL ma-
turation. We discovered 5 apolipoproteins (A1, A2, A4, C3 and E) that
possess cholesterol efflux and anti-inflammatory functions and 10
complement and 7 immunoglobin proteins that mostly contribute to
immune response and anti-inflammatory functions. We propose cho-
lesterol efflux and immune response as the essential functions for all
HDL particles, amino acid metabolism as a special function of S-HDL,
and anti-coagulation as a special function for M-HDL. Pon1 is recruited
into M/L-HDL to precess its antioxidatiove function because Pon1 ap-
pears only in M/L-HDL. ApoE is incoerperated into L-HDL to optimize
its cholesterial clearance function because ApoE was only detected in L-
HDL. Our discoveries provide a novel basis of HDL structural and
functional heterogeneity and suggest that HDL is a powerful molecular
vehicle for multisystem metabolic and molecular regulation and is an
accessible therapeutic target.
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